In 2026, Malaysia recorded zero production of vaccine antigens (5 million doses), ranking 33-th out of 197 countries. This gap reflects the nation's current lack of dedicated facilities for synthesizing active pharmaceutical ingredients for vaccines. Nevertheless, Malaysia is far from a biotech backwater: it has carved a strong niche in contract manufacturing of finished dosage forms and is a regional leader in vaccine fill-and-finish operations. Government incentives are now steering investment toward domestic R&D and upstream production, aiming to close the antigen gap in the coming decade.
Malaysia world ranking
Country position on the scale from last to first place for this indicator.
Change over time
Change in indicator over the available period.
Values — million doses
Top countries by Vaccine antigens production
Where Malaysia stands in the world ranking.
People also search for
Other pages of the reference by this indicator.